Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKCA Akcea Therapeutics	$18.17	$18.16	$8.00 ▼ $21.70	$1.85B	1.45	361,806 shs	N/A
EPZM Epizyme	$1.47	$1.47	$0.41 ▼ $5.80	$247.44M	-0.41	3.23 million shs	7,960 shs
SAGE Sage Therapeutics	$9.12 -0.3%	$7.41	$4.62 ▼ $13.47	$572.98M	0.18	1.29 million shs	2.72 million shs
TBPH Theravance Biopharma	$11.03 -1.7%	$10.00	$7.44 ▼ $11.82	$561.02M	-0.09	268,518 shs	208,255 shs
ZYME Zymeworks	$12.55 +0.6%	$12.20	$8.32 ▼ $17.70	$873.19M	1.17	588,165 shs	420,695 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKCA Akcea Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
EPZM Epizyme	0.00%	0.00%	0.00%	0.00%	0.00%
SAGE Sage Therapeutics	0.00%	-1.61%	+40.77%	+15.09%	-15.75%
TBPH Theravance Biopharma	0.00%	+5.55%	+21.30%	+25.64%	+32.31%
ZYME Zymeworks	0.00%	-0.08%	+6.86%	+4.70%	+46.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	3.1933 of 5 stars	2.0	2.0	0.0	4.0	2.5	1.7	0.6
TBPH Theravance Biopharma	2.0038 of 5 stars	3.3	0.0	0.0	0.0	2.6	2.5	0.6
ZYME Zymeworks	1.9199 of 5 stars	3.5	1.0	0.0	0.0	1.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKCA Akcea Therapeutics	0.00	N/A	N/A	N/A
EPZM Epizyme	0.00	N/A	N/A	N/A
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.05% Downside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	50.50% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	67.33% Upside

Current Analyst Ratings Breakdown

Latest EPZM, ZYME, AKCA, TBPH, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKCA Akcea Therapeutics	$488.54M	3.78	$0.51 per share	35.54	$5.78 per share	3.14
EPZM Epizyme	$37.43M	6.61	N/A	N/A	($0.54) per share	-2.72
SAGE Sage Therapeutics	$41.24M	13.85	N/A	N/A	$7.60 per share	1.20
TBPH Theravance Biopharma	$64.38M	8.57	N/A	N/A	$3.57 per share	3.09
ZYME Zymeworks	$93.38M	9.35	N/A	N/A	$6.63 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKCA Akcea Therapeutics	$40.77M	$0.48	N/A	N/A	N/A	-12.34%	-8.94%	-8.02%	N/A
EPZM Epizyme	-$251.12M	-$1.72	N/A	N/A	N/A	-391.90%	-2,459.33%	-69.74%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	31.51	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest EPZM, ZYME, AKCA, TBPH, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKCA Akcea Therapeutics	N/A	12.17	11.78
EPZM Epizyme	N/A	5.35	5.19
SAGE Sage Therapeutics	N/A	9.13	9.13
TBPH Theravance Biopharma	N/A	4.77	4.77
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKCA Akcea Therapeutics	19.27%
EPZM Epizyme	76.45%
SAGE Sage Therapeutics	99.22%
TBPH Theravance Biopharma	99.10%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AKCA Akcea Therapeutics	1.50%
EPZM Epizyme	23.40%
SAGE Sage Therapeutics	5.50%
TBPH Theravance Biopharma	6.90%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKCA Akcea Therapeutics	248	101.60 million	N/A	Optionable
EPZM Epizyme	250	168.33 million	128.97 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	46.55 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

EPZM, ZYME, AKCA, TBPH, and SAGE Headlines

Recent News About These Companies

Zymeworks Amends Warrant Agreement with EcoR1 Capital

June 27 at 4:59 PM | tipranks.com

ZYME - Zymeworks Inc Registered Shs Dividends - Morningstar

June 27 at 3:30 PM | morningstar.comM

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from Brokerages

June 24, 2025 | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Duncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)

June 19, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)

June 15, 2025 | marketbeat.com

Zymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?

June 13, 2025 | marketbeat.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)

June 12, 2025 | marketbeat.com

Wellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)

June 5, 2025 | marketbeat.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC

June 2, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)

May 31, 2025 | marketbeat.com

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

May 30, 2025 | endpts.comE

China's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract Cancer

May 30, 2025 | precisionmedicineonline.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPZM, ZYME, AKCA, TBPH, and SAGE Company Descriptions

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics NASDAQ:SAGE

$9.12 -0.03 (-0.33%)

As of 04:00 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Theravance Biopharma NASDAQ:TBPH

$11.03 -0.19 (-1.69%)

As of 04:00 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Zymeworks NYSE:ZYME

$12.55 +0.08 (+0.64%)

As of 04:00 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time